• All
  • Financials
  • Insiders
Webull provides the latest Statera BioPharma Inc (STAB) stock and general news. This information may help you make smarter investment decisions.
About STAB
Statera BioPharma, Inc., formerly Cytocom, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies targeting autoimmune, neutropenia/anemia, viruses and cancers. Its Advanced Immunomodulating Multi-component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200, STAT-400 and STAT-600 AIMS programs. Its STAT-200 program includes STAT-201, STAT-205, STAT-203 and STAT-202. STAT-201 is focused the treatment of Crohn’s disease. STAT-205 is focused on treatment of acute and post-acute coronavirus (COVID 19). Its STAT-400 programs include STAT-401 and STAT-400. STAT-401 is an injectable pentapeptide that is targeted for patients with pancreatic cancer.